Hemophilia Treatment Drugs Market to reach US$ 15,000.0 Mn by 2026

Hemophilia Treatment Drugs Market

Hemophilia Treatment Drugs Market Segmentation by Product Type - Recombinant Coagulation Factor Concentrates, Plasma derived Coagulation Factor Concentrates; Disease Indication Hemophilia A, Hemophilia B, Others; Distribution Channel Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Forecast 2018 - 2026

Š2019 Transparency Market Research, All Rights Reserved

Table of Content Sr. No.

Content

Chapter 1

Preface

Chapter 2

Assumptions and Research Methodology

Chapter 3

Executive Summary : Global Hemophilia Treatment Drugs Market

Chapter 4

Market Overview

Chapter 5

Market Outlook

Chapter 6

Global Hemophilia Treatment Drugs Market Analysis and Forecast, by Product Type

Chapter 7

Global Hemophilia Treatment Drugs Market Analysis and Forecast, by Disease Indication

Chapter 8

Global Hemophilia Treatment Drugs Market Analysis and Forecast, by Distribution Channel

Chapter 9

Global Hemophilia Treatment Drugs Market Analysis and Forecast, by Region

Chapter 10

North America Hemophilia Treatment Drugs Market Analysis and Forecast

Chapter 11

Europe Hemophilia Treatment Drugs Market Analysis and Forecast

Chapter 12

Asia Pacific Hemophilia Treatment Drugs Market Analysis and Forecast

Chapter 13

Latin America Hemophilia Treatment Drugs Market Analysis and Forecast

Chapter 14

Middle East & Africa Hemophilia Treatment Drugs Market Analysis and Forecast

Chapter 15

Competition Landscape Š2019 Transparency Market Research, All Rights Reserved

Hemophilia Treatment Drugs Market - Snapshot

Increase in R&D investment by key players for developing new drugs for the treatment of hemophilia.

Rise in demand for long-acting replacement therapies and nonfactor therapies are anticipated to fuel the growth of the global market during the forecast period.

Hemophilia treatment drugs market is driven by government initiatives such as nationwide network of hemophilia treatment centers (HTCs) funded by the Federal Government in the U.S. Many of the HTCs are located at major university medical and research centers. The Federal Government in the U.S. provides funds for more than 100 HTCs. Š2019 Transparency Market Research, All Rights Reserved

Report Highlights The global hemophilia treatment drugs market is anticipated to reach US$ 15,000 Mn by 2026, expanding at a CAGR of 5% from 2018 to 2026.

Patients who are provided care and treated at HTCs are less likely to have hospitalization and bleeding complications than those who avail care elsewhere.

On the basis of product type, the recombinant coagulation factor concentrates segment is expected to dominate the hemophilia treatment drugs market during the forecast period.

Request For Sample

Š2019 Transparency Market Research, All Rights Reserved

Continue..

North America is expected to dominate the global hemophilia treatment drugs market in the coming years.

Some of the prominent players operating in the global hemophilia treatment drugs market are Pfizer, Inc., Kedrion, Shire Plc., CSL Behring, Novo Nordisk A/S Novo Nordisk A/S accounted for the second largest share of the global hemophilia treatment drugs market in 2017 due to wide range of hemophilia drugs and robust pipeline.

Request For Brochure

Š2019 Transparency Market Research, All Rights Reserved

Contact

To know more about us, please visit our website:

www.transparencymarketresearch.com For sales queries or new topics email us on:

sales@transparencymarketresearch.com

Thank You Š2019 Transparency Market Research, All Rights Reserved